Dewcell showcases 바카라사이트 안내 platelet technology at ASH and ISSCR, signaling commercialization and expansion into regenerative medicine

[by Kang, In Hyo] Dewcell, a developer of 바카라사이트 안내 platelet technologies, announced on December 16 that it presented its stem cell-based 바카라사이트 안내 platelet production technology at the 67th American Society of Hematology (ASH) Annual Meeting, held in Orlando, Florida, from December 4 to 9 (local time).

At the meeting, Dewcell presented updates on the development of its scale-up process using a 50-liter incubator, together with its plans for future clinical trials and commercialization. The company also outlined the potential for large-scale production of 바카라사이트 안내 platelets and its strategy for real-world application, attracting considerable interest from leading global scholars and industry figures.

Currently, Dewcell has completed the installation of a 50-liter incubator at its research facility and is in the final phase of technological development aimed at establishing a large-scale production system. In addition, the company plans to secure a Good Manufacturing Practice (GMP)-certified facility in Anyang, Gyeonggi Province, within the year, where it will transfer its technology and progressively finalize its mass production infrastructure. These steps are expected to further accelerate the commercialization of 바카라사이트 안내 platelets.

In addition, Dewcell presented research findings on the tissue regeneration effects of its 바카라사이트 안내 platelets at the International Society for Stem Cell Research (ISSCR) Boston International Symposium, held in Boston, United States, from December 11 to 13.

The study involved administering Dewcell’s artificial platelets to an animal model of osteoarthritis to evaluate their tissue regenerative properties and the activity of platelet-derived growth factors. The findings showed that Dewcell's artificial platelets were structurally, genetically, and functionally equivalent to blood-derived platelets, as demonstrated through comparative analyses. When applied to damaged cartilage cells and osteoarthritis animal models, the artificial platelets exhibited analgesic and anti-inflammatory effects, as well as potential cartilage regeneration activity. Notably, a single administration in the animal model produced marked pain relief and tissue regeneration, suggesting the potential of artificial platelets as a novel therapeutic modality.

The company noted that the study’s findings attracted considerable interest from researchers in regenerative medicine and global industry stakeholders. “Through this presentation at an international conference, we have confirmed the potential for our artificial platelets to be applied not only as blood substitutes but also as therapeutic agents. Moving forward, we plan to accelerate the development of artificial platelet-based treatments in parallel with applications as blood substitutes,” a Dewcell official said.